Research and Markets - More than 110 (Monoclonal Antibody) mAb Products Currently in Clinical Trials and Likely to Play Important Role in Advancement of the Field

Research and Markets has announced the addition of "New Directions in Monoclonal Antibodies: Technologies, Markets, Competition" to their offering.

(PRWEB) October 26, 2004 -- Research and Markets (http://www.researchandmarkets.com/reports/c7919) has announced the addition of "New Directions in Monoclonal Antibodies: Technologies, Markets, Competition" to their offering.

This report reviews the broad drug development effort that is focused on bringing improved mAb-based products to the market, including those used for drug discovery research, in vivo diagnostics, and therapeutic applications.

The monoclonal antibody market has experienced explosive growth in the nearly 30 years since the process for creating mAbs was introduced. More than fifteen therapeutic mAbs have been approved, several of which have reached blockbuster status. Numerous diagnostic mAbs have also been approved, making this one of the fastest growing fields in biotechnology. Today, the industry is working as furiously as ever to perfect the design and production of mAbs for therapeutic, diagnostic, and other purposes. This report evaluates the salient issues in these endeavors.

New Directions in Monoclonal Antibodies examines the more than 110 mAb products currently in clinical trials, as well as the products that are already available and those still at the preclinical stage that are likely to play an important role in the advancement of the field.

The report presents further analysis to evaluate the market potential for monoclonal antibodies in development for a variety of diseases. It reviews some general observations concerning commercialization of mAbs, then addresses the major disease categories, including patient numbers for diseases of interest; competing therapeutics already on the market, particularly those that have recently gained regulatory approval; and, where available, estimates of market sizes in dollars. Only those conditions for which drug candidates have been identified or which have been prominently mentioned as potential markets by pharmaceutical companies in the field are covered

Contents include:
- Background and Scientific Overview: Antibodies and Monoclonal Antibodies

- Current and Emerging Technologies: Improving Monoclonal Antibody Design and Production
Key Breakthroughs in the First 30 Years of Monoclonal Antibody Development
Monoclonal Antibody Libraries and Display Technologies
Other Technologies for Designing Monoclonal Antibodies
Alternative Antibody Formats
Technologies for Improving Monoclonal Antibody Characteristics
Technologies for Improving Monoclonal Antibody Production

- Marketed and Emerging Monoclonal Antibodies: Present and Future Therapeutics and In Vivo Diagnostics
Approved Therapeutic Monoclonal Antibodies
Profiles of Therapeutic Monoclonal Antibodies Approved for Marketing
Monoclonal Antibodies in Development for Cancer
Monoclonal Antibodies in Development for Immunologic Diseases
Monoclonal Antibodies in Development for Infectious Diseases
Antibodies in Development for Cardiovascular Diseases
Other Therapeutic Antibodies in Development
Approved and Developmental Diagnostic Antibodies

-Profiles of Diagnostic Monoclonal Antibodies Approved for Marketing

-Companies Developing Diagnostic Monoclonal Antibodies

- Business and Strategic Outlook: Market Potential for Monoclonal Antibodies and Trends in the Field
General Trends
The Market for Therapeutic Monoclonal Antibodies
The Market for Diagnostic Monoclonal Antibodies

Company Profiles
-AERES Biomedical Ltd.
-Affibody
-ARIUS Research Inc.
-Biogen Idec
-BioInvent
-Biovation Limited
-Centocor, Inc.
-Crucell
-Discerna UK
-Domantis
-Epitomics, Inc.
-Genentech, Inc.
-Genmab A/S
-GTC Biotherapeutics
-Human Genome Sciences, Inc.
-ImmunoGen, Inc.
-Raven Biotechnologies, Inc.

-Expert Commentaries
Walter Blattler, Ph.D., ImmunoGen, Inc.
Carl Borrebaeck, BioInvent
Rathin Das, Affitech A/S
Robert Ladner, Dyax Corp.
Nils Lonberg, Medarex
Simon Moroney, MorphoSys
Clay B. Siegall, Seattle Genetics, Inc.
Stephen Worsley, Raven Biotechnologies, Inc.
Geoff Yarranton, KaloBios Pharmaceuticals Inc.

For more information visit http://www.researchandmarkets.com/reports/c7919

Laura Wood
Senior Manager
Research and Markets
press@researchandmarkets.com
Fax: +353 1 4100 980

###